We provided hitherto undocumented evidence that MEX3A promoted EMT, invasion and metastasis of CRC cells by activating the Wnt/β-catenin signaling pathway, suggesting that MEX3A could be a new therapeutic target in CRC. Here, MEX3A is linked to colorectal carcinoma.